risedronic acid has been researched along with Scleroderma, Systemic in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Botzoris, VG | 1 |
| Argyropoulou, MI | 1 |
| Voulgari, PV | 1 |
| Zikou, AK | 1 |
| Drosos, AA | 1 |
1 review available for risedronic acid and Scleroderma, Systemic
| Article | Year |
|---|---|
Heterotopic ossification in systemic sclerosis.
Topics: Acetaminophen; Colchicine; Drug Therapy, Combination; Etidronic Acid; Humans; Knee Joint; Male; Midd | 2009 |